What Happened

Researchers at CERN, the European physics laboratory famous for the Large Hadron Collider, have successfully adapted particle accelerator technology to create FLASH radiotherapy—a cancer treatment that compresses weeks of radiation into millisecond bursts. The technique delivers over 40 Gray of radiation (equivalent to 20 conventional sessions) in less than 0.1 seconds, using 200 MeV linear electron accelerators.

Physicist Walter Wuensch leads the multimillion-dollar project, working alongside Institut Curie researchers Vincent Favaudon and Marie-Catherine Vozenin. Their 140 MeV systems can penetrate up to 20 centimeters deep into the body, reaching most tumor locations with surgical precision.

The technology requires dose rates 1000 times higher than conventional radiotherapy, achieved through electromagnetic wave control and precision beam steering originally developed for fundamental physics research. Multiple companies are now racing to commercialize hospital-sized versions of these systems.

Why It Matters

FLASH radiotherapy solves the fundamental trade-off that has plagued cancer treatment for decades: destroying tumors without devastating healthy tissue. Conventional radiotherapy requires 20-40 sessions over several weeks, causing significant side effects from accumulated damage to healthy cells. FLASH delivers equivalent tumor-killing power in a single millisecond burst with minimal collateral damage.

This breakthrough could dramatically expand global cancer care access. Currently, only 10% of cancer patients in low-income countries receive radiotherapy, partly due to the infrastructure required for multi-week treatment protocols. Single-session FLASH treatments could make cancer care feasible in underserved regions while improving outcomes in developed countries.

Approximately 50% of all cancer patients receive radiotherapy as part of their treatment. FLASH technology could transform the experience for millions, eliminating the daily hospital visits, cumulative side effects, and treatment delays that characterize current protocols.

Background

The discovery originated from an accidental observation in the 1990s during mouse lung experiments. Researchers expected severe tissue damage when exposing healthy tissue to high radiation doses but found none when the delivery was ultra-rapid. This counterintuitive result challenged fundamental assumptions about radiation biology.

For decades, scientists couldn’t explain why FLASH worked or reliably reproduce the effect. The current leading theory involves differential oxygen metabolism between healthy and cancerous cells during ultra-short radiation exposure, though the mechanism remains largely mysterious.

CERN’s involvement began when cancer researchers realized they needed particle accelerator expertise to achieve the extreme precision and power required for FLASH delivery. The same electromagnetic wave control technology used to accelerate particles to near-light speed in the Large Hadron Collider proved essential for creating therapeutic radiation beams.

What’s Next

Human clinical trials are currently underway at the University of Cincinnati and CHUV hospital in Switzerland, marking the transition from laboratory research to patient treatment. Early results suggest the technique maintains its healthy tissue-sparing properties in humans while effectively targeting tumors.

Commercial deployment faces significant technical challenges. FLASH requires completely new radiation measurement systems capable of monitoring millisecond doses with extreme precision. Unlike conventional radiotherapy, where treatments can be paused or adjusted mid-session, FLASH offers no opportunity for real-time corrections during the brief exposure.

Experts predict routine clinical use within 10 years, though initial systems will likely cost significantly more than conventional linear accelerators. The infrastructure investment could be offset by elimination of multi-week treatment protocols and reduced need for managing long-term side effects.

Several medical device manufacturers are developing hospital-scale FLASH systems, suggesting competitive commercial availability within the current decade. Success could fundamentally reshape cancer care globally, making effective treatment accessible to populations currently underserved by existing radiotherapy infrastructure.